Zomedica Corp Stock Price, News & Analysis

Zomedica (OTCQB:ZOMDF) announced its upcoming Fourth Friday at Four webinar on August 22, 2025, focusing on their VETIGEL® hemostatic gel product. The webinar, scheduled for 4:00 PM ET, will showcase this plant-based solution designed for rapid bleeding control in veterinary medicine.

VETIGEL® offers veterinary professionals a quick and efficient method for managing soft tissue and superficial wounds through its syringe-based delivery system. The product accelerates clot formation and seals wounds, eliminating the need for traditional methods like manual pressure or cautery. The webinar will feature clinical case studies, real-world outcomes, and testimonials from veterinary professionals, followed by a live Q&A session with Zomedica's product and commercial leaders.

Zomedica (OTCQB:ZOMDF), a veterinary health company, reported strong Q2 2025 financial results with revenue growing 14% to $7.0 million, marking its 18th consecutive quarter of year-over-year growth. The company achieved 67% gross margins and maintained a robust liquidity position of $59.1 million.

Key highlights include 86% growth in the Diagnostics segment, primarily driven by TRUFORMA platform adoption, and 21% growth in Consumable sales to $5.3 million. The Therapeutic Device segment, comprising PulseVet and Assisi products, grew 8% to $6.2 million. International sales increased by 13% year-over-year. Operating expenses decreased by $0.7 million, though the company reported a net loss of $7.4 million.

Zomedica (OTCQB:ZOMDF) announces its upcoming Fourth Friday at Four webinar on July 25, 2025, focusing on their Assisi product line of targeted Pulsed Electromagnetic Field (tPEMF) therapy devices. The webinar will showcase their drug-free solutions including the Assisi Loop®, Assisi Loop Lounge®, and Calmer Canine® products.

The session will feature insights into tPEMF technology, clinical outcomes, and real-world applications in veterinary care. Led by Nicole Westfall, Senior VP of Marketing, and Mialisa Gluckert, Senior Director of Assisi Commercialization, the webinar will demonstrate how these non-invasive treatments are revolutionizing pain and inflammation management in companion animals.

Zomedica (OTCQB:ZOMDF) has announced a strategic sponsorship agreement between its PulseVet shock wave device and the World Equestrian Center - Ocala (WEC), establishing PulseVet as the official shock wave therapy provider at the venue. The partnership includes comprehensive brand visibility through arena signage, digital promotions, and features in WEC publications.

The collaboration aims to enhance veterinary care for elite equine athletes by providing non-invasive shock wave therapy for musculoskeletal injuries. The agreement includes on-site educational resources, promotional materials, and hospitality privileges during WEC events, including discounted lodging and VIP access.

Zomedica (OTCQB:ZOMDF) has been granted a new U.S. Patent (No. 12,299,917 B2) for its TRUVIEW microscope, specifically covering Methods and Systems for Slide Imaging Calibration. The patent strengthens the company's intellectual property portfolio, which now comprises 77 U.S. patents, 144 international patents, 33 U.S. trademarks, and 107 foreign trademarks.

Bill Campbell, VP of Imaging Systems and TRUVIEW's inventor, emphasized the patent's significance in validating their focusing system innovation. CEO Larry Heaton highlighted how this protection enables continued investment in market expansion while maintaining product uniqueness.

Zomedica Corp. (ZOM) has announced its upcoming Fourth Friday at Four webinar, scheduled for June 27, 2025, at 4:00 PM ET. The webinar will focus on the company's TRUFORMA diagnostic platform, an in-clinic system designed for point-of-care veterinary diagnostics. The TRUFORMA system enables veterinarians to perform precise, rapid, and reliable testing without relying on external labs. The webinar will include platform demonstrations, expert insights on diagnostic workflow transformation, case studies of improved patient outcomes, and an interactive Q&A session with Zomedica's leadership and technical experts. CEO Larry Heaton emphasizes the company's commitment to empowering veterinarians with tools that enhance diagnostic capabilities while improving practice efficiency and profitability.

Zomedica (OTCQB:ZOMDF) has announced significant enhancements to its equine insulin assay for the TRUFORMA Diagnostic Platform. The update features an extended dynamic range, increased by 60% from its previous version, and introduces an innovative automatic sample dilution function. This advancement allows veterinarians to measure insulin levels at the highest ranges without additional steps or increased time-to-result.

The new automatic dilution feature eliminates the need for manual dilution protocols for samples exceeding 250 µU/mL, streamlining the testing process. The enhancement maintains test consistency while freeing staff from additional tasks. This development positions TRUFORMA as having the widest dynamic range available both at Point of Care and compared to Reference Labs.

Zomedica Corp. (OTCQB:ZOMDF) has announced the launch of a new monthly webinar series called "Fourth Friday at Four" starting May 23rd, 2025. The series aims to showcase the company's innovative veterinary health products and technologies to investors, veterinarians, and industry partners.

The webinars will highlight Zomedica's product portfolio including the PulseVet® Shock Wave system for musculoskeletal healing, Assisi Loop® and Calmer Canine for pain management and anxiety, TRUFORMA® diagnostic platform, TRUVIEW® Digital Cytology System, VETGuardian® monitoring system, and VETIGEL® hemostatic gel. CEO Larry Heaton emphasized that the series will focus on building a community of professionals while providing insights into the company's technologies and growth strategy.

Zomedica (OTCQB:ZOMDF) has launched the Equine Asthma Clinical Registry, a groundbreaking program utilizing PulseVet® shock wave therapy as a non-invasive, drug-free treatment for equine asthma. The initiative aims to gather real-world clinical evidence on the effectiveness of electrohydraulic extracorporeal shock wave therapy (ESWT) in treating respiratory conditions in horses.

Initial studies show promising results, with 58 horses completing treatment without adverse events. The registry allows veterinary clinics to enroll up to 20 horses, requiring three scheduled visits over 4-6 weeks. Equine asthma affects approximately 15% of horses over age seven, impacting their performance and quality of life. The program offers participating clinics product credits while contributing to vital research in advancing equine respiratory care.